The Role of Continuing Cemiplimab in Second-Line Therapy After Progression
Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after progression on prior treatments. Continuing cemiplimab post-progression can enhance survival outcomes by maintaining immune system activation against cancer cells.
Video content above is prompted by the following:
- Discuss the role of continuing cemiplimab in second-line therapy after progression.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Recent Videos
Related Content
